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Abstract Proprotein convertases (PCs) have been proposed to
play a role in tumor necrosis factor-K converting enzyme
(TACE) processing/activation. Using the furin-de¢cient LoVo
cells, as well as the furin-pro¢cient synoviocytes and HT1080
cells expressing the furin inhibitor K1-PDX, we demonstrate
that furin activity alone is not su⁄cient for e¡ective maturation
and activation of the TACE enzyme. Data from in vitro and in
vivo cleavage assays indicate that PACE-4, PC5/PC6, PC1 and
PC2 can directly cleave the TACE protein and/or peptide. PC
inhibition in macrophages reduced the release of soluble TNF-K
from transmembrane pro-TNF-K. We therefore conclude that
furin, in addition to other candidate PCs, is involved in TACE
maturation and activation.
6 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
As implied by its acronym, TACE (tumor necrosis factor-K
converting enzyme) or ADAM-17 was originally cloned and
named for its ability to cleave and convert tumor necrosis
factor-K (TNF-K) into a soluble form [1,2]. Since then,
TACE has been demonstrated to solubilize a variety of sub-
strates including transforming growth factor-K (TGF-K) [3],
members of the membrane-bound epidermal growth factor
(EGF) family ligand, the Notch receptor [4], the chemokine
fractalkine [5], both TNF receptors, TNFR-I [6] and TNFR-
II [3], macrophage/colony-stimulating factor receptor [7],
L-selectin [3], and the L-amyloid precursor protein [8]. As
predicted by the wide variety of TACE substrates, in vivo
inhibition of TACE or disruption of the TACE gene resulted
in the death of mice between embryonic day 17.5 and the ¢rst
day after birth [3] due to a number of developmental defects
reminiscent of those seen in mice lacking TGF-K or EGF
receptor [9]. In addition, TACE inhibition alone or in combi-
nation with matrix metalloproteinases (MMPs) has been dem-
onstrated to have therapeutic potential in a variety of patho-
logical conditions including polycystic kidney disease [10],
airway in£ammation [11] and arthritis [12,13]. Because of
the wide physiological and pathological importance of
TACE, much attention has been paid to its structure and
mechanism of activation.
Similar to other members of the ADAM family, the struc-
ture of TACE is characterized by distinct domains which in-
clude a prodomain, a metalloprotease and a disintegrin do-
main, followed by a cysteine-rich domain containing an EGF-
like repeat, a transmembrane domain and a cytoplasmic tail.
The prodomain of catalytically active TACE is now known to
act as an inhibitor of the protease via a cysteine switch mech-
anism consisting of an intramolecular complex between an
unpaired cysteine residue of the prodomain and the zinc
atom in the active catalytic site [14]. TACE can be activated
by nitrosation, alkylation, and oxidation, resulting in the dis-
sociation of the cysteine thiol^zinc linkage and thereby release
of the prodomain inhibitory function [14,15]. Also, prodo-
main removal is likely to be a prerequisite for the activation
of the TACE protease. This activation pathway is predomi-
nant for the activation of several MMPs and appears to be
mediated by furin and related proprotein convertases (PCs)
[16,17]. Despite the potential importance of this activation
mechanism for the TACE enzyme, little is still known about
the identity of the convertase(s) involved in this processing.
Members of the PC family are potential candidates as a
TACE convertase as ¢rst predicted by the identi¢cation of a
putative furin-like recognition site (212RVKR) at the junction
between the TACE prodomain and the catalytic domain [1,2].
Also, co-expression of pro-TACE and furin in insect cells
results in e⁄cient maturation of TACE [17]. TACE prodo-
main removal has been reported to occur in a late Golgi
compartment, a feature also consistent with a role for furin-
like PCs in this process [18].
The mammalian PCs comprise a complex family of enzymes
that includes furin, PC1, PC2, PC4, PC5/PC6 and PC7 [19].
While most studies have focussed on substrate cleavage by
furin, it is now becoming more evident that the other conver-
tases may perform redundant cleavage functions due to rec-
ognition of similar basic cleavage sites (e.g. KR or RR)
[20,21]. In the case of furin, this convertase has been demon-
strated to mediate the activation of various proenzymes in-
volved in matrix remodeling such as the membrane type forms
of the MMPs and most proteolytic active ADAMs (e.g.
ADAM-9 [22], ADAM-10 [23], ADAM-12 [24], ADAM-15
[25], ADAM-19 [26], and ADAMTS4 [27]). However, some
metalloproteases such as ADAM-10 have also been shown to
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be activated by other furin-like PCs [23]. The sum of these
data leads us to conclude that while furin plays an important
role in MMP and ADAM activation, it is likely that other
convertases are also involved. In this report, we used several
gene complementation and enzyme inhibition systems to
present evidence that furin is a convertase involved, in part,
in the processing and activation of TACE. This result con-
¢rms very recent studies indicating the requirement of furin in
TACE maturation [28,29]. We also uncovered the existence of
candidate PCs including PACE-4, PC5/PC6, PC1 and PC2
with the ability to speci¢cally process the TACE enzyme.
2. Materials and methods
2.1. Cell cultures
Adenocarcinoma LoVo cells (ATCC, Rockville, MD, USA) were
maintained in F-12 nutrient mixture (Gibco BRL, Burlington, ON,
Canada) containing 10% fetal bovine serum (FBS; Bio Media, Drum-
mondville, QC, Canada). HT1080 cells (human ¢brosarcoma; ATCC)
were cultured in minimum essential medium (Gibco BRL) with 10%
FBS. Rat synovial cells were isolated and cultured as previously de-
scribed [30]. Jurkat cells (human acute T leukemia cells ; ATCC) were
cultured in RPMI 1640 medium (Gibco BRL) with 10% FBS. Human
THP-1 cells (human acute monocytic leukemia from ATCC) were
maintained in RPMI 1640 medium with 10% FBS, 2.5 g/l D-glucose,
1 mM sodium pyruvate (Gibco BRL) and 10 WM L-mercaptoethanol
(Sigma, Oakville, ON, Canada). MonoMac-1 cells (human acute
monocytic leukemia from DSMZ, Braunschweig, Germany) were cul-
tured in RPMI 1640 medium with 5% FBS, 1 mM sodium pyruvate
and 100 WM non-essential amino acids (Gibco BRL).
2.2. Cell transfectants
LoVo cells transfected with furin were a kind gift of Dr. N. Kita-
mura (Institute for Liver Research, Kansai Medical University, Osa-
ka, Japan) [31]. The control clone (LoVo Neo) and two clones trans-
fected with furin (LoVo Fur1 and LoVo Fur2) were maintained in
Ham F-12 medium supplemented with 10% FBS and 600 Wg/ml ge-
neticin (G-418, Gibco BRL).
The AT-PDX gene, kindly provided by Gary Thomas (University
of Oregon, Portland, OR, USA), was inserted into the EcoRI/ApaI
cloning site of a pcDNA3 plasmid vector containing a geneticin resis-
tance cassette. pcDNA3-AT-PDX or the empty control vector was
transfected into HT1080 cells and plasmid-expressing cells were se-
lected using 600 Wg/ml geneticin. One control clone (HT1080 Neo)
and one clone expressing the highest level of HT1080-AT-PDX (out
of nine obtained), as determined by Western blotting, were retained.
2.3. Western blot analysis
Cells (2U106) were seeded onto 60 mm Petri dishes in culture me-
dium containing 1% FBS and treated with varying concentrations of
dec-RVKR-cmk (Bachem, Torrance, CA, USA). For experiments not
involving inhibitors, 2.5U106 cells were seeded onto 10 cm Petri
dishes in culture medium containing 10% FBS. After 24 h incubation,
Western blot analysis was performed as previously described [30] us-
ing 1:1000 rabbit anti-TACE polyclonal antibodies (Chemicon). As
previously described, LoVo cells were infected with vaccinia recombi-
nant for PC1/PC3, PACE-4, PC5/PC6, furin or PC7 or an unrelated
control vaccinia recombinant both used at a multiplicity of infection
(MOI) of 5 [21]. Eighteen hours after infection, cells were lysed, ali-
quots were separated on reducing sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis (SDS^PAGE) gels and immunoblotted using
rabbit anti-TACE polyclonal antibodies.
2.4. Adenoviral vector construction and cell infection
The gene encoding full length AT-PDX was inserted into the multi-
ple cloning site of the transfer vector pAd-TR5F-DC-GFP and placed
under the control of a modi¢ed cytomegalovirus (CMV) promoter
containing a tetracycline-regulated expression cassette [32,33] and ex-
pressed together with the green £uorescent protein (GFP) tracer. The
production of adenoviral vectors was performed as described [33] and
titered by £ow cytometry using GFP £uorescence as a marker of
infection. AdCMVtTA, expressing the transactivator tTA under con-
trol of a constitutive CMV promoter, was obtained from Dr. Bernard
Massie (Biotechnology Research Institute of Montreal, Montreal, QC,
Canada).
2.5. TNF-K release
MonoMac-1 and THP-1 cells (1U106) were preincubated for 22 h
with varying concentrations of dec-RVKR-cmk. Then, 500 ng/ml of
Escherichia coli lipopolysaccharide (LPS) O127:B8 and 100 ng/ml
phorbol 12-myristate 13-acetate (PMA; Sigma) were added. After
3 h, cells and supernatants were harvested and lysates were prepared
as described above. An enzyme-linked immunosorbent assay
(Quantikine0 from RpD System, Minneapolis, MN, USA) was
used to measure supernatant and cell-associated TNF-K concentra-
tions.
2.6. TNFR p75 shedding
LoVo Neo and LoVo Fur2 cells (2U106) were seeded onto 60 mm
Petri dishes in culture medium containing 1% FBS and treated with
100 WM dec-RVKR-cmk. After 24 h of incubation, cells were ¢xed in
2% paraformaldehyde and permeabilized with 0.1% saponin. For im-
munolabeling, cells were incubated overnight with R-phycoerythrin-
conjugated anti-TNFR-II antibody (1:20; Caltag Laboratories, Bur-
lingame, CA, USA), R-phycoerythrin-conjugated anti-IgM (1:100;
Jackson ImmunoResearch, West Grove, PA, USA), or rabbit anti-
TACE antibody (1:100; Chemicon). Cells were washed and incubated
with £uorescein-conjugated anti-rabbit IgG (1:1000; Jackson Immu-
noResearch) in phosphate-bu¡ered saline containing 0.1% bovine se-
rum albumin and 0.1% saponin for 30 min. A FACScan £ow cytom-
eter (Becton Dickinson, San Jose, CA, USA) was used for
£uorescence detection. Results were analyzed using the CellQuest1
software (Becton Dickinson).
2.7. In vitro cleavage assays
Recombinant PCs were expressed in Schneider 2 cells and puri¢ed
as described [34]. Peptide cleavage assays were performed with two
TACE peptides (long and short form) spanning the activation site in
the N-terminal region. The sequences of the TACE peptides are:
PEELVHRVKRRADPDPMK (18-mer TACE peptide) and LVDR-
EPPEELVHRVKRRADPDP (22-mer TACE peptide). The peptides
were synthesized by the Sheldon Biotechnology Institute (Montreal,
QC, Canada). In vitro cleavage assays consisted of 5 U enzyme
(1 U=1 pmol of AMC released/h) and 5 nmol of each peptide. Anal-
ysis of cleavage was carried out either by direct injection of the re-
action mixture on high performance liquid chromatography (HPLC)
or through mass spectrometry (MS) analysis. Laser desorption/ioniza-
tion MS analysis was performed with a Applied Biosystems (Framing-
ham, MA, USA) voyager-DE STR time of £ight mass spectrometer
with delayer extraction, operating with a pulsed nitrogen laser at 337
nm S.
3. Results and discussion
3.1. Role of furin in the processing of TACE
We ¢rst investigated the proportion of unprocessed pro-
TACE and mature TACE in various hematopoietic and
non-hematopoietic cell types (Fig. 1). The cells used include
the furin-positive cell lines THP-1, Jurkat, HT1080 and rat
synoviocytes as well as the furin-de¢cient LoVo cells. Cell
lysates were assessed by immunoblotting for the production
of TACE proteolytic fragments using TACE-speci¢c antibod-
ies directed against the cytoplasmic domain of the enzyme, so
both the precursor (pro-TACE) and the mature forms
(TACE) would be detected. As demonstrated in Fig. 1,
TACE is predominantly expressed as a 100 kDa mature
form in all of these cell lines except in LoVo cells where an
additional 110 kDa band (pro-TACE) is observed. This sug-
gests that the TACE enzyme is completely processed in all the
furin-positive cell lines tested so far.
To investigate the role of furin in TACE maturation, we
next carried out complementation studies in LoVo cells (Fig.
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1B). These are human colon carcinoma cells which have a
point mutation in both alleles of the fur gene leading to pro-
duction of a defective enzyme [35]. Immunoblotting of cell
lysates from control LoVo Neo cells revealed that these cells
expressed approximately 50% of processed TACE as seen by
the relative intensity of the mature TACE and the pro-TACE
immunoreactive bands (Fig. 1B). Genetic complementation of
these cells with furin resulted in a strong diminution of the
immunoreactive pro-TACE band with concomitant increase
in the intensity of the 100 kDa mature species. Thus trans-
fection of the fur gene restored the normal processing pattern
observed in furin-positive cell lines, indicating that furin was
responsible for the discrepancy between LoVo cells and the
other wild-type cells. To provide further evidence for the role
of furin in TACE maturation, we veri¢ed the impact of furin
inhibition in furin-positive cell lines (Fig. 1C,D). Stable trans-
fectants (HT1080 PDX) were generated from human ¢brosar-
coma HT1080 cells using a vector encoding AT-PDX (Fig.
1C), a potent furin inhibitor, which also inhibits PC6 to
some extent with a Ki of 0.6 and 2.3 nM respectively [36].
As expected, AT-PDX expression resulted in the reappearance
of the pro-TACE band, which was absent in control HT1080
Neo cells (Fig. 1C, left panel). As observed in LoVo cell
lysates, the processed pro-TACE band was also immunode-
Fig. 1. Maturation of TACE by furin. A: Western blot analysis of TACE expression in cell lysates of Jurkat, THP-1 or LoVo Neo cells.
B: LoVo Neo cells transfected with either an empty vector (Neo) or the fur gene (Fur1, Fur2). C: HT1080 cells transfected with either an
empty vector (Neo) or AT-PDX (PDX) (left panel); and zymography of HT1080 supernatants showing MMP-2 maturation (right panel).
D: Primary cultures of rat synovial cells were infected for 40 h with AdTr5PDX, AdTr5GFP, or AdCMVtTa at the indicated MOIs. The infec-
tion was carried out in the presence of doxycycline (1 Wg/ml). Western blotting of cell lysates using anti-TACE antibodies (left panel); and £ow
cytometry analysis of GFP-AT-PDX-positive cells (right panel).
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tected in furin-inhibited HT1080 cells. As a control, the mat-
uration/activation of MMP-2, an event known to be under
the control of furin through the activation of MT1-MMP,
was completely blocked in AT-PDX-expressing HT1080 cells
(Fig. 1C, right panel), indicating that the serpin was expressed
at levels su⁄cient to completely block furin activity in these
cells.
Next, we also inhibited furin in rat synoviocytes (Fig. 1D),
a cell culture relevant to rheumatoid arthritis. Because of low
transfection rates and di⁄culty in producing stable transfec-
tants with primary synovial cell cultures, a viral gene delivery
system was chosen to introduce AT-PDX into these cells. For
this, we used a modi¢ed adenovirus vector (AdTR5) in which
the K1-AT-PDX gene is placed under the negative control of a
tetracycline/doxycycline-regulated promoter that is sensitive to
low concentrations of doxycycline in cell cultures [37]. As
illustrated in Fig. 1D (left panel), lane 3, we observed about
20% accumulation of the pro-TACE form in synoviocytes co-
infected with the adenoviral vector encoding for AT-PDX and
with AdCMVtTA, while this does not occur in either non-
infected (lane 1) or control adenovirus-infected synoviocytes
(lane 2). In addition, when the tTA blocker doxycycline (1 Wg/
ml) is added to the culture medium (lane 4), only the mature
form of TACE is present indicating speci¢city to the AT-PDX
inhibitor. The observed 20% accumulation of the pro-TACE
form in synoviocytes may seems low compared to the 40^50%
accumulation in HT1080 PDX cells (Fig. 1C). However, this
likely re£ects the e⁄ciency of PDX delivery using the adeno-
viral system that is estimated to be 60% (Fig. 1D, right panel).
The observed role of furin in TACE maturation is consis-
tent with the already described or proposed role of furin
in the activation of other metalloproteases including MT1-
MMP [17], and several proteolytically active ADAMs (e.g.
ADAM-9 [22], ADAM-10 [23], ADAM-12 [24], ADAM-15
[25], ADAM-19 [26], and ADAMTS4 [27]).
3.2. Role of PCs other than furin in TACE maturation
Because complete inhibition of pro-TACE processing could
not be achieved by AT-PDX or in furin-de¢cient LoVo Neo
cells, our results further suggest that other enzymes, present in
cells and not inhibited by the AT-PDX serpin, participate in
the TACE maturation process. Since the TACE processing
site (RVKRs) could also be recognized by other members
of the PC family, it is possible that PCs other than furin
also participate in the TACE maturation process. To assess
this possibility, we used dec-RVKR-cmk, a synthetic peptide
that mimics the proprotein recognition site, and that has been
demonstrated to inhibit the enzymatic activity of most PCs,
including furin, PC5/PC6, PC1, PC2, PACE-4 and PC7 [36].
LoVo Neo and LoVo Fur2 cells were incubated for 24 h with
several concentrations of that PC inhibitor, and cell lysates
were assessed for TACE maturation by Western blotting as
described above. The addition of dec-RVKR-cmk to LoVo
Neo cells resulted in a concentration-dependent inhibition of
TACE maturation, with maximal e¡ect observed at 100 WM
dec-RVKR-cmk (Fig. 2A), while a scrambled CMK peptide
had no inhibitory e¡ect (data not shown). As illustrated in
Fig. 2B dec-RVKR-cmk inhibition is statistically signi¢cant at
P6 0.01. Similar but more dramatic results were obtained in
LoVo Fur2 cells, given that TACE maturation is complete in
untreated LoVo Fur2 cells. No additional e¡ect was observed
when using a concentration of 200 WM in either LoVo Neo or
Fur2 cells (data not shown). These results indicated that PCs
other than furin are involved in the processing of TACE.
Further, using a combination of the hydroxamate-based me-
talloprotease inhibitor BB-3103 and dec-RVKR-cmk used at
optimal concentrations (0.5 WM and 100 WM, respectively) we
did not observe additional inhibitory e¡ects (data not shown),
suggesting that metalloproteases, including potential catalysis
or autocatalysis by TACE itself, are not involved in the
TACE maturation process.
Fig. 2. Maturation of TACE PCs. A: LoVo Neo and LoVo Fur2 cells were incubated for 24 h with various concentrations of dec-RVKR-
cmk, lysed and subjected to Western blot analysis as described in Section 2. B: The relative densities of the pro-TACE and TACE bands from
LoVo Neo cells treated or not with dec-RVKR-cmk (100 WM) were determined using NIH Image software. The paired t-test was used for sta-
tistical analysis. n=4.
FEBS 27777 5-11-03
N. Srour et al./FEBS Letters 554 (2003) 275^283278
3.3. In vitro cleavage of TACE peptides by PCs
To determine if PCs cleave TACE directly or act through
an intermediate, we resorted to an in vitro cleavage assay. An
oligopeptide that encompasses the furin-like consensus recog-
nition motif PEELVHRVKRsRADPDPMK (18-mer TACE
peptide) found at the junction between the proregion and the
active enzyme sequence and a N-terminally extended peptide
that encompasses both the consensus furin recognition se-
quence and a second potential PC recognition site (mono-R)
[38] LVDRsEPPEELVHRVKRsRADPD (22-mer TACE
peptide) were synthesized and incubated with puri¢ed re-
combinant PCs. As demonstrated in Fig. 3A (top right panel),
the analysis of the control unprocessed 18-mer TACE peptide
revealed a retention time of 29 min. When the 18-mer TACE
peptide was incubated with furin for 4 h (Fig. 3A, middle
panel), the unprocessed peptide peak (29 min) was diminished
while two peaks, corresponding to cleavage fragments of the
original peptide, appeared at retention times of 16 and 22 min.
This indicates that furin has the ability to directly cleave
TACE at the junction between the mature enzyme and the
proregion. Moreover, when incubation was conducted over-
night (Fig. 3A, middle right panel), the 29 min peak disap-
peared, indicating that all of the original peptide had been
processed. A similar pattern was observed when PC2 was
used instead of furin, at both incubation times (Fig. 3A, bot-
tom panel). In addition, PC1 and PC5/PC6 were also able to
cleave the 18-mer TACE peptide (data not shown).
In Fig. 3B, MS analysis con¢rms the expected furin cleav-
age site for the 18-mer TACE peptide with a fragment with a
predicted mass of 1262.48. Similar results were observed for
all cleavage-competent PCs including PC1, PC2 and PC5/PC6.
HPLC and MS analysis were also performed with the 22-mer
TACE peptide. HPLC analysis resulted in the same cleavage
pro¢le of the 22-mer peptide as previously observed with the
18-mer, i.e. the same cleavage-competent PCs were observed
(data not shown). MS analysis of the obtained fragments re-
sulted in a mass of 1972.33 (predicted mass 1972.28) that
corresponds to cleavage at the RVRRs cleavage site and
not the monobasic DRs site. Therefore, the MS data con¢rm
that furin, PC1, PC2 and PC5/PC6 cleave each of the TACE
peptides at the expected RVRRs furin-like cleavage site. It
has been shown that overexpression of TACE in CHO cells
results in the secretion of the processed enzyme with two
N-termini at Val212 and Arg215 [39]. Our MS results support
the notion that the Val212 N-terminus is unlikely to be a result
of a PC cleavage event, possibly because of the presence of a
valine at the P1P position of monobasic sites, which is not
favored by this type of enzyme [38].
3.4. In vivo cleavage of TACE by PCs
To de¢ne if PCs cleave TACE e¡ectively in an intact cell
system, we used recombinant vaccinia virus for cell delivery of
PC1/PC3, PACE-4 and PC5/6 in LoVo cells. After 18 h in-
fection, cell lysates were analyzed for TACE maturation by
immunoblotting. As illustrated in Fig. 3C, LoVo cells infected
with control recombinant virus (vaccinia virus:pro-opiomela-
nocortin (POMC)) exhibited about 50% cleavage of pro-
TACE as evidenced by the detection of the pro-TACE and
the mature TACE bands (Fig. 3C). In contrast, infection with
vaccinia virus encoding PC1, PACE-4 or PC5/PC6 resulted in
a signi¢cant increase in the relative proportion of the proteo-
lytically processed mature TACE form. Taken together with
the results indicating that furin is required, in part, for in vivo
TACE processing, our ¢ndings suggest furin PACE-4, PC5/
PC6 and PC1 are able to process TACE in intact cells. We
have not assessed the ability of PC2 to process TACE in
LoVo cells since these cells lacks the 7B2 chaperone needed
for proper PC2 routing stability and activity [40].
3.5. Impact of the inhibition of TACE maturation on TACE
shedding activities
TACE has been shown to mediate cleavage of TNF-K as
well as a variety of ectodomains including the TNF p75 re-
ceptor (TNFR-II) [3]. To investigate whether the levels of
TACE maturation observed in LoVo transfectants impact
TACE-related sheddase activity, we ¢rst measured cell surface
p75 TNFR expression as a marker for TACE cell surface
activity. Brie£y, LoVo Neo and LoVo Fur2 cell samples
were labeled with anti-TACE or anti-TNF p75 receptor anti-
bodies and cell £uorescence was analyzed on a FACScan.
Results expressed in Fig. 4A indicated that furin complemen-
tation of LoVo cells reduces cell surface p75 TNF receptor
expression by about 50% (from 60% to 32%) without signi¢-
cant impact on the levels of cell surface TACE. Similar results
have also been observed in MonoMac-1 and THP-1 cell lines
(data not shown), in this case we used dec-RVKR-cmk-in-
duced inhibition of TACE maturation. To ensure that the
discrepancy observed in TNFR p75 cell surface expression
between LoVo Neo and LoVo Fur2 cells was not due to a
di¡erence in the levels of TACE expression between clones,
LoVo Fur2 cells were incubated with dec-RVKR-cmk and
samples were processed for cell surface TNFR p75 by immu-
nodetection. As predicted, inhibition of PCs by dec-RVKR-
cmk led to higher levels of TNFR p75 cell surface expression
(Fig. 4B), which correlates with lower levels of TACE matu-
ration in these conditions. Taken together, our results also
indicate that furin activity increases TNFR p75 shedding.
Therefore removal of the TACE prodomain by furin increases
its activity, as postulated.
Next, we measured the ability of dec-RVKR-CH2Cl to
block TNF-K release from the human monocytic cells THP-
1 and MonoMac-1, which naturally produce TNF-K. For this,
cells were preincubated for 22 h with varying concentrations
of dec-RVKR-CH2Cl and TNF-K production was induced by
LPS and PMA. Results expressed in Fig. 5A indicated that
treatment of these cells with a PC inhibitor blocked about
50% of TNF-K release with an ED50 around 20 WM. To en-
sure that the inhibition of TNF-K was due to changes in
sheddase activity, we next measured TNF-K shedding rate
as currently de¢ned by ratios of supernatant to cell-associated
TNF-K. The results indicate that increasing doses of dec-
RVKR-CH2Cl resulted in a gradual decrease in supernatant
to cell-associated TNF-K ratios (Fig. 5B). These results sug-
gest that inhibition of TACE processing leads to an impair-
ment in TACE sheddase activities.
Therefore, we demonstrate in this study that among the PC
family of enzymes, furin, PC5/PC6, PC1 and PC2 are all
TACE-competent convertases and that cleavage at the furin
site results in an increased sheddase activity. Redundancy be-
tween members of the PC family is well established and a
recent example is the ability of furin, PC5/PC6, and PC7 to
cleave with similar e⁄cacy a peptide containing the processing
site of an Ebola virus surface glycoprotein [41]. Other exam-
ples include pro-insulin-like growth factor-1 receptor process-
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ing by furin and PC5A, but not by PACE-4 or PC7 [42] and
pro-endothelin by furin and PC7 [20].
Just prior to the submission of this article, Peiretti et al.
[28,] and Endres et al. [29] published results indicating that
furin was responsible, in part, for TACE processing in LoVo
cells as well as various cell types including HT29 and HEK293
cells. In addition, an increased amount of processed TACE
was observed in cells overexpressing PC7 [29]. Since LoVo
cells are known to express PACE-4 and PC7, they concluded
that PC7 was responsible, in part, for basal levels of TACE
processing in these cells [29]. Our results indicating that
PACE-4 can process the TACE enzyme in vitro and in cells
further suggest that both PACE-4 and PC7 convertases are
involved in TACE maturation by LoVo cells.
PC5/PC6 is known to be expressed in many endocrine and
non-endocrine tissues, with a particularly high expression in
the gut [43,44]. In the present study, we observed that PC6 is a
TACE-competent convertase both in vitro and in vivo. Inter-
estingly, high levels of TACE have been detected in normal
gut and the median TACE level was increased in patients with
active ulcerative colitis [45]. This raises the possibility that the
activation of TACE by PC6 is one of the mechanisms that
Fig. 4. Impact of the inhibition of TACE maturation by a PC inhibitor on p75 TNFR cell surface expression. A: Flow cytometry analysis of
LoVo Neo and LoVo Fur2 stained with control (shaded), anti-TNFR p75 (unshaded, top panels) or anti-TACE (unshaded, middle panels)
antibodies. A representative experiment out of two is illustrated. B: LoVo Fur2 cells were treated or not with 100 WM dec-RVKR-cmk and
stained using anti-TNFR p75 antibody. Indicated in the top right corner of each panel is the percentage of cells positive for TNFR p75 or
TACE.
Fig. 3. In vitro and in vivo maturation of TACE-derived peptides by PCs. A: An 18-mer TACE was incubated for 4 h or overnight with puri-
¢ed recombinant furin or PC2. Represented are the results of HPLC analysis. The two top panels represent the analysis of a blank control
(left) or the TACE peptide incubated without PCs (right). B: MS analysis of the cleaved (A) TACE short (18-mer) and (B) TACE long (22-
mer) peptides. Predicted molecular masses after cleavage are 1262.48 for the TACE short peptide and 1972.28 for the TACE long peptide.
C: LoVo cells were infected with vaccinia recombinant for control protein (POMC), or the convertases PC1, PACE-4 or PC5/PC6. Eighteen
hours after infection, cells were lysed, aliquots were separated on reducing SDS^PAGE gels and immunoblotted using rabbit anti-TACE poly-
clonal antibodies (1:1000).
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account for elevated expression of TNF-K in this pathological
condition.
The observation that PC1 and PC2 also cleaved the TACE
peptides suggests potential roles of these enzymes for TACE
activation in neuroendocrine tissues and cells as well as in
certain types of immune cells. Indeed, TACE expression has
been localized in brain tissue, more speci¢cally in distinct
neuronal cell populations, including the pyramidal neurons
of the cerebral cortex and the granular cell layer neurons of
the hippocampus [46]. Since PC1 and PC2 were clearly shown
to be expressed in these same neuronal populations [47], it is
likely that PC1 and/or PC2 are involved in the cellular acti-
vation of TACE within neurons. Regarding the immune sys-
tem, PC1 and PC2 were also demonstrated to be expressed
within polymorphonuclear leukocytes, alveolar macrophages
and spleen mononuclear cells [48]. Since macrophages and
polymorphonuclear leukocytes are known to produce large
quantities of TNF-K, it is conceivable that TACE maturation
by PC2 or PC1/PC3 could be an alternative modulation mech-
anism for TNF-K production in these cells.
PCs are known to be responsible for the maturation of
several molecules involved in extracellular matrix-associated
diseases. For instance, furin mRNA is upregulated in a rat
collagen-induced model of arthritis (A. Lebel et al., unpub-
lished results). Moreover, the increased levels of furin in joints
correlate with the intensity of joint in£ammation. Furin has
been shown to be responsible for the maturation of the TGF-
L1 precursor and in turn, TGF-L1 in synovial cells upregulates
the furin-encoding fur gene, generating a unique enzyme/sub-
strate ampli¢cation loop that can be of fundamental impor-
tance in in£ammatory conditions [30]. For example, the am-
pli¢ed levels of furin and TGF-L can cooperate to increase the
levels of ADAMTS4 [49], a newly uncovered furin substrate
[27] responsible for the degradation of the matrix protein
aggrecan, a major component of cartilage. Beside ADAMTS4,
furin can also participate in the maturation of other proteases,
which are involved in collagen degradation, including MT1-
MMP, a metalloprotease known to activate proMMP2 [50^
52] and proMMP13 [53]. Our demonstration that TACE is a
PC substrate therefore adds to the possibility that these en-
zymes are important players in the pathogenesis of in£amma-
tory and matrix-associated diseases such as rheumatoid arthri-
tis. In this context PCs could be a target to prevent the
formation of bioactive proteins involved in arthritis, thereby
resulting in the prevention or regression of the disease.
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